Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs
- 283 Downloads
Several different types of drugs acting on the central nervous system (CNS) have previously been associated with an increased risk of suicide and suicidal ideation (broadly referred to as suicide). However, a differential association between brand and generic CNS drugs and suicide has not been reported.
This study compares suicide adverse event rates for brand versus generic CNS drugs using multiple sources of data.
Selected examples of CNS drugs (sertraline, gabapentin, zolpidem, and methylphenidate) were evaluated via the US FDA Adverse Event Reporting System (FAERS) for a hypothesis-generating study, and then via administrative claims and electronic health record (EHR) data for a more rigorous retrospective cohort study. Disproportionality analyses with reporting odds ratios and 95% confidence intervals (CIs) were used in the FAERS analyses to quantify the association between each drug and reported suicide. For the cohort studies, Cox proportional hazards models were used, controlling for demographic and clinical characteristics as well as the background risk of suicide in the insured population.
The FAERS analyses found significantly lower suicide reporting rates for brands compared with generics for all four studied products (Breslow–Day P < 0.05). In the claims- and EHR-based cohort study, the adjusted hazard ratio (HR) was statistically significant only for sertraline (HR 0.58; 95% CI 0.38–0.88).
Suicide reporting rates were disproportionately larger for generic than for brand CNS drugs in FAERS and adjusted retrospective cohort analyses remained significant only for sertraline. However, even for sertraline, temporal confounding related to the close proximity of black box warnings and generic availability is possible. Additional analyses in larger data sources with additional drugs are needed.
Compliance with Ethical Standards
Conflicts of interest
In the past 3 years, Richard A. Hansen has provided expert testimony for Daiichi Sankyo. Richard Hansen and Jingjing Qian also have received grant funding from US FDA Grant U01FD005272 and contract HHSF2232015101102C, and these grants are directly related to the general topic of this manuscript. Dr. Hansen also received funding from National Institute of Health grant 2R01GM097618-04, which is related to but did not directly fund this work. Ning Cheng, Md. Motiur Rahman, Yasser Alatawi, Jingjing Qian, Peggy L. Peissig, Richard L. Berg, and David Page have no conflicts of interest that are directly relevant to the content of this study. Views expressed in written materials or publications and by speakers do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.
This study was supported by the U.S. Food and Drug Administration through Grant U01FD005272 and contract HHSF2232015101102C. A National Institute of Health Grant 2R01GM097618-04 provided related support but did not directly fund this study.
The study was approved by the Auburn University Institutional Review Board for research involving human subjects (protocol 14-465 EP1410).
- 1.World Health Organization. America’s State of Mind Report 2011 [cited 2017 Feb 09]. http://apps.who.int/medicinedocs/en/d/Js19032en/.
- 2.BBC. Research. Therapeutic Drugs for Central Nervous System (CNS) Disorders: Technologies and Global Markets 2010 [cited 2017 Feb 09]. http://www.bccresearch.com/market-research/pharmaceuticals/drugs-central-nervous-system-disorders-phm068a.html.
- 5.Express Scripts. Drug Trend Report 2016 [cited 2017 Feb 09]. https://lab.express-scripts.com/lab/drug-trend-report.
- 12.Kesselheim AS, Darrow JJ. Hatch–Waxman turns 30: do we need a re-designed approach for the modern era. Yale J Health Pol’y L Ethics. 2015;15:293.Google Scholar
- 13.Danzis SD. The Hatch–Waxman act: history, structure, and legacy. Antitrust Law J. 2003;71(2):585–608.Google Scholar
- 14.Del Tacca M, Pasqualetti G, Di Paolo A, Virdis A, Massimetti G, Gori G, et al. Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers. Br J Clin Pharmacol. 2009;68(1):34–42.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.U.S. Food and Drug Administration. Bupropion Hydrochloride Extended-Release 300 mg Bioequivalence Studies 2014 [cited 2017 Feb 09]. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm322161.htm.
- 17.U.S. Food and Drug Administration. Methylphenidate Hydrochloride Extended Release Tablets (generic Concerta) made by Mallinckrodt and Kudco 2014 [cited 2017 Feb 09]. http://www.fda.gov/drugs/drugsafety/ucm422568.htm.
- 19.Collett GA, Song K, Jaramillo CA, Potter JS, Finley EP, Pugh MJ. Prevalence of central nervous system polypharmacy and associations with overdose and suicide-related behaviors in Iraq and Afghanistan War veterans in VA care 2010–2011. Drugs Real World Outcomes. 2016;3:45–52.CrossRefPubMedCentralGoogle Scholar
- 26.Los Angeles Times. Generic drugs' hidden downside [cited 16 March 2017]. Available from: http://articles.latimes.com/2007/dec/17/news/OE-WAX17.
- 30.U.S. Food and Drug Administration. What is FAERS 2016 [cited 2016 June 15]. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm.
- 32.Hansen RA, Qian J, Berg RL, Linneman JG, Seoane-Vazquez E, Dutcher S, et al. Comparison of outcomes following a switch from a brand to an authorized vs. independent generic drug. Clin Pharmacol Ther. 2016. http://dx.doi.org/10.1002/cpt.591.
- 34.Activities MDfR. Standardised MedDRA Queries 2017 [cited 2017 June 25]. http://www.meddra.org/how-to-use/tools/smqs.
- 35.Finley EP, Bollinger M, Noël PH, Amuan ME, Copeland LA, Pugh JA, et al. A national cohort study of the association between the polytrauma clinical triad and suicide-related behavior among US Veterans who served in Iraq and Afghanistan. Am J Public Health. 2015;105(2):380–7.CrossRefPubMedPubMedCentralGoogle Scholar
- 47.Miller M. Questions & answers. I’ve been taking Zoloft Recently, my pharmacist filled my prescription with a generic form of the drug. Does the brand name matter? Harv Ment Health Lett Harv Med Sch. 2007;23(8):8.Google Scholar
- 50.Iyer G, Marimuthu SP, Segal JB, Singh S. An algorithm to identify generic drugs in the FDA adverse event reporting system. Drug Saf. 2017;40(9):799–808.Google Scholar